NCT05356143View on ClinicalTrials.gov

A Comparative Study of Rupatadine 10 mg Tablets and Clarinex® 5 mg Tablets Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

December 2, 2021

Primary Completion Date

January 13, 2022

Study Completion Date

January 5, 2023

Conditions
Healthy
Interventions
DRUG

Rupatadine

Oral single dose 10 mg tablet

Trial Locations (1)

M1S 3V6

Pharma Medica Research Inc., Toronto

All Listed Sponsors
lead

J. Uriach and Company

INDUSTRY

NCT05356143 - A Comparative Study of Rupatadine 10 mg Tablets and Clarinex® 5 mg Tablets Under Fasting Conditions | Biotech Hunter | Biotech Hunter